Identyfikator artykułu ATH-JHQBPX
· Tier 2 papers
· Immunology
Classification of current anticancer immunotherapies CC-BY
Zarchiwizowana praca w otwartym dostępie, zaimportowana do długoterminowego zachowania (pochodzenie: Oncotarget). Nie jest to zgłoszenie do AthenXiv, więc nie ma historii wersji ani historii znaczników czasu.
- Pierwotnie opublikowano Dec 18, 2014 UTC
- Prawa: CC-BY (nie odnotowano daty wygaśnięcia)
- Dodano do AthenXiv Oct 3, 2026 UTC
Przesłany w imieniu autora przez AthenXiv (UW2JTS24Y)
Streszczenie
// Lorenzo Galluzzi 1,2,3,4,* , Erika Vacchelli 1,2,3 , José-Manuel Bravo-San Pedro 1,2,3 , Aitziber Buqué 1,2,3 , Laura Senovilla 1,2,3 , Elisa Elena Baracco 1,2,3,5 , Norma Bloy 1,2,3,5 , Francesca Castoldi 1,2,3,5,6 , Jean-Pierre Abastado 7 , Patrizia Agostinis 8 , Ron N. Apte 9 , Fernando Aranda 1,2,3,10 , Maha Ayyoub 11,12 , Philipp Beckhove 13 , Jean-Yves Blay 14,15 , Laura Bracci 16 , Anne Caignard 17,18 , Chiara Castelli 19 , Federica Cavallo 20 , Estaban Celis 21 , Vincenzo Cerundolo 22 , Aled Clayton 23,24 , Mario P. Colombo 19 , Lisa Coussens 25 , Madhav V. Dhodapkar 26 , Alexander M. Eggermont 3 , Douglas T. Fearon 27 , Wolf H. Fridman 2,4,28,29 , Jitka Fučíková 6,30 , Dmitry I. Gabrilovich 31 , Jérôme Galon 2,4,28,32 , Abhishek Garg 8 , François Ghiringhelli 33,34,35 , Giuseppe Giaccone 36,37 , Eli Gilboa 38 , Sacha Gnjatic 39 , Axel Hoos 40 , Anne Hosmalin 4,41,42,43 , Dirk Jäger 44 , Pawel Kalinski 45,46,47 , Klas Kärre 48 , Oliver Kepp 1,2,49 , Rolf Kiessling 50 , John M. Kirkwood 51 , Eva Klein 48 , Alexander Knuth 52 , Claire E. Lewis 53 , Roland Liblau 54,55,56 , Michael T. Lotze 45,46 , Enrico Lugli 57 , Jean-Pierre Mach 58 , Fabrizio Mattei 16 , Domenico Mavilio 57,59 , Ignacio Melero 60,61 , Cornelis J. Melief 62,63 , Elizabeth A. Mittendorf 64 , Lorenzo Moretta 65 , Adekunke Odunsi 66 , Hideho Okada 67 , Anna Karolina Palucka 68 , Marcus E. Peter 69 , Kenneth J. Pienta 70 , Angel Porgador 9 , George C. Prendergast 71,72,73 , Gabriel A. Rabinovich 74 , Nicholas P. Restifo 75 , Naiyer Rizvi 76 , Catherine Sautès-Fridman 2,4,28,29 , Hans Schreiber 77 , Barbara Seliger 78 , Hiroshi Shiku 79 , Bruno Silva-Santos 80 , Mark J. Smyth 81,82 , Daniel E. Speiser 83,84 , Radek Spisek 6,30 , Pramod K. Srivastava 85,86 , James E. Talmadge 87 , Eric Tartour 4,88,89,90 , Sjoerd H. Van Der Burg 91 , Benoît J. Van Den Eynde 92,93,94 , Richard Vile 95 , Hermann Wagner 96 , Jeffrey S. Weber 97 , Theresa L. Whiteside 46,98 , Jedd D. Wolchok 99,100 , Laurence Zitvogel 3,101,102 , Weiping Zou 103 and Guido Kroemer 1,2,4,49,104,* 1 Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France 2 INSERM, U1138, Paris, France 3 Gustave Roussy Cancer Campus, Villejuif, France 4 Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France 5 Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France 6 Sotio a.c., Prague, Czech Republic 7 Pole d’innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France 8 Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium 9 The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel 10 Group of Immune receptors of the Innate and Adaptive System, Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 11 INSERM, U1102, Saint Herblain, France 12 Institut de Cancérologie de l’Ouest, Saint Herblain, France 13 Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany 14 Equipe 11, Centre Léon Bérard (CLR), Lyon, France 15 Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France 16 Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy 17 INSERM, U1160, Paris, France 18 Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France 19 Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy 20 Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 21 Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA 22 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK 23 Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK 24 Velindre Cancer Centre, Cardiff, UK 25 Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA 26 Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA 27 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA 28 Université Pierre et Marie Curie/Paris VI, Paris, France 29 Equipe 13, Centre de Recherche des Cordeliers, Paris, France 30 Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic 31 Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 32 Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France 33 INSERM, UMR866, Dijon, France 34 Centre Georges François Leclerc, Dijon, France 35 Université de Bourgogne, Dijon, France 36 Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA 37 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA 38 Dept. of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA 39 Sect. of Hematology/Oncology, Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA 40 Glaxo Smith Kline, Cancer Immunotherapy Consortium, Collegeville, PA, USA 41 INSERM, U1016, Paris, France 42 CNRS, UMR8104, Paris, France 43 Hôpital Cochin, AP-HP, Paris, France 44 National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany 45 Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA, USA 46 University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA 47 Dept. of Immunology and Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA
Słowa kluczowe: Immunotherapy and Immune Responses, Immunology, Immunology and Microbiology, Life Sciences
Licencja: CC-BY
Czytaj online
Odnośniki zewnętrzne
- DOI Oncotarget https://doi.org/10.18632/oncotarget.2998
Cytuj ten artykuł
Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean‐Pierre Abastado, Patrizia Agostinis, Ron N. Apte, Fernando Aranda, Maha Ayyoub, Philipp Beckhove, Jean‐Yves Blay, Laura Bracci, Anne Caignard, Chiara Castelli, Federica Cavallo, Estaban Celis, Vincenzo Cerundolo, Aled Clayton, Mario P. Colombo, Lisa M. Coussens, Madhav V. Dhodapkar (2026).
Classification of current anticancer immunotherapies. AthenXiv.
https://athenxiv.com/paper/ATH-JHQBPX